Project Grant R56HL167875
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$608K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
The National Heart Lung and Blood Institute (NHLBI) awarded a $111,626 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to investigate ways to target macrophage populations and attenuate pulmonary hypertension associated with sickle cell disease. The 2-year project aims to determine if modifying iron release from the ferroportin transporter can alter CD169+ macrophage and adaptive immune cell quantities, phenotypes, and oxidative status (Aim 1);...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
The National Heart Lung and Blood Institute (NHLBI) awarded a $1,103,783 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois for a research project titled "Molecular Mechanism and Targeting of Chronic Pain in Sickle Cell Disease". The 7-year project, running from February 2025 to January 2032, aims to advance the understanding of the molecular and neurobiological mechanisms underlying chronic pain in sickle cell disease (SCD) and develop...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $573,821 to the University of North Carolina at Chapel Hill to conduct research on the role of endothelin-1 (ET-1) signaling in regulating renal iron handling in sickle cell disease. The goal is to elucidate the molecular mechanisms by which ET-1/ETA receptor activation promotes renal iron overload, and to assess the potential of ETA receptor antagonism as...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant will fund the development of a high-throughput platform to measure the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology will...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The research aims to: 1) define the relationship between SCD adverse outcomes and single-cell biochemical/mechanical properties to identify the most promising biomarkers; 2) define the...
This Project Grant award, identified as R01HL170118, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, totaling $495,159.00, will fund research to investigate the role of the protein CARMIL1 in regulating endothelial cell barrier function and its potential impact on acute respiratory distress syndrome (ARDS). The study, to be conducted by the University of Illinois, will use...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...